Scarica l'app Stockscreener
3.34
7.05%
0.22
Dopo l'orario di chiusura:
3.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Altimmune Inc Borsa (ALT) Ultime notizie
Altimmune, Inc. (ALT) gains analyst support as pemvidutide advances - msn.com
Altimmune Inc.’s New Price Target Ignites Investor Interest - timothysykes.com
Altimmune’s Stock Target Raised as MASH Program Gains Momentum - timothysykes.com
Gitlab, Altimmune, Cheniere, Pacific Biosciences, Hercules Shock Wall Street - TipRanks
ALT stock has nearly halved in the past year, so why does Wall Street see almost 500% upside? - MSN
Altimmune Inc Phase 2b Topline 48-Week Data Conference Call Transcript - GuruFocus
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts - Sahm
Insider Buying: Gregory Weaver Acquires 10,000 Shares of Altimmune Inc (ALT) - GuruFocus
Altimmune (ALT) CFO adds 10,000 shares in open-market stock purchase - Stock Titan
Altimmune (NASDAQ: ALT) CEO adds 15,000 shares in open-market buy - Stock Titan
Insider Buying: Gregory Weaver Acquires 10,000 Shares of Altimmu - GuruFocus
Options Flow: Will Altimmune Inc announce a stock split2026 Market WrapUp & Real-Time Buy Signal Alerts - baoquankhu1.vn
Top 10 stocks under $5 that could triple - MSN
ALT (Altimmune) Common Stock : $0.01 Mil (As of Dec. 2025) - GuruFocus
ALT (Altimmune) Shares Outstanding (Diluted Average) : 105.82 Mil (As of Dec. 2025) - GuruFocus
ALT (Altimmune) 5-Year RORE % : -16.56% (As of Dec. 2025) - GuruFocus
Pullback Watch: Can Altimmune Inc disrupt its industrySell Signal & Low Drawdown Investment Strategies - baoquankhu1.vn
Altimmune Inc. (ALT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ALT (Altimmune) FCF Yield % : -17.19 (As of Mar. 27, 2026) - GuruFocus
ALT (Altimmune) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2025) - GuruFocus
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
Jefferies reiterates Buy on Altimmune stock, keeps $28 target - Investing.com UK
Jefferies reiterates Buy on Altimmune stock, keeps $28 target By Investing.com - Investing.com India
Vanguard subsidiaries disaggregate holdings; Altimmune (NASDAQ: ALT) showing 0 shares - Stock Titan
ALT (Altimmune) EPS without NRI : $-1.01 (TTM As of Dec. 2025) - GuruFocus
Altimmune appoints Luis Sanay as vice president of investor relations to strengthen financial communications - Traders Union
ALT Pemvidutide Uncovered: How It Stands Apart in MASH - Bitget
Altimmune Stock: Balanced Perspective With Major Catalysts Expected in 2026 - Bitget
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms - Yahoo Finance Singapore
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts - TradingView
ALT Pemvidutide Explained: What Makes It Different in MASH - Yahoo Finance
Altimmune a new buy at Truist on pemvidutide promise - MSN
HC Wainwright bullish on Altimmune (ALT) amid growing focus on treatments for metabolic and liver diseases - MSN
H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases - Insider Monkey
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning - Benzinga
ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan
Altimmune outlines 1,800-patient phase III MASH trial and signals cash runway into 2028 as pemvidutide advances - MSN
Growth Value: Can Altimmune Inc stock outperform in a bear marketWeekly Market Report & Consistent Income Trade Recommendations - baoquankhu1.vn
Viking Therapeutics: Phase 3 Obesity Data Feels Like A Coin Toss (Rating Downgrade) (VKTX) - Seeking Alpha
ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN
Truist initiates Altimmune stock coverage with buy rating on drug potential - Investing.com Australia
Altimmune (ALT) Gains Buy Rating with Promising MASH Treatment - GuruFocus
Altimmune (NASDAQ:ALT) Now Covered by Analysts at Truist Financial - MarketBeat
What is HC Wainwright's Estimate for Altimmune Q1 Earnings? - MarketBeat
Altimmune (FRA:3G0) NonCurrent Deferred Revenue : €0.14 Mil (As of Dec. 2025) - GuruFocus
H.C. Wainwright raises Altimmune stock price target on MASH focus By Investing.com - Investing.com Australia
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):